TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B Stock
Certificat
DE000SB7SMX0
| Market Closed - Deutsche Boerse AG 15:43:10 2024-06-07 EDT | ||
| 20.36 EUR | +2.36% |
|
| Current month | +9.23% | ||
| 1 month | +16.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 20.36 | +2.36% |
| 24-06-06 | 19.89 | +1.17% |
| 24-06-05 | 19.66 | +1.87% |
| 24-06-04 | 19.3 | +3.32% |
| 24-06-03 | 18.68 | +0.21% |
Delayed Quote Deutsche Boerse AG
Last update June 07, 2024 at 03:43 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SB7SMX |
| ISIN | DE000SB7SMX0 |
| Date issued | 2020-11-02 |
| Strike | 230.7 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.41 € |
|---|---|
| Lowest since issue | 0.053 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
- Stock Market
- Certificates
- Certificat
